Colorectal cancer (CRC) remains one of the most common cancers in the world, and approximately 5–10 % of cases can be attributed to hereditary syndromes, including familial adenomatous polyposis, Lynch syndrome, MYH-associated polyposis, the hamartomatous syndromes, and their variants. Extensive research has identified the genes associated with many of these syndromes. Screening and management of patients with these conditions differs from that of the general population, and genetic testing and counselling has become crucial in this process. In this review, we discuss the different hereditary polyposis syndromes and their genetics, and emphasise approaches to the screening and surveillance of patients in the hope of preventing the morbidity and mortality currently associated with CRC.
Share this Article
Related Content In Gastrointestinal Oncology
Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances
touchREVIEWS in Oncology & Haematology. 2021;17(1):18-22 DOI: https://doi.org/10.17925/OHR.2021.17.1.18
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract, accounting for 0.1–3.0% of all GI malignancies, and 80% of all GI sarcomas.1–5 While GISTs can occur throughout the entire GI tract, with similar male/female incidence, 60% of cases usually present in the stomach, and about 30% in the small […]
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020
European Oncology & Haematology. 2020;16(1):11
Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!